Replies to post #153526 on Avid Bioservices Inc (CDMO)

[geocappy1]

Maybe management wants what may be and BP wants a price based on what is. Doesn't mean a partner doesn't want pphm's IP. Simply there has not been a meeting of the minds on value.

[ws_guy]

The answer lies somewhere in between.

PPHM management want to go alone for P3.

1) A lot of PPHM executive may loose job if the go for merger or acquisition , as garbage cleaning is very first step after merger.

2) PPHM executive rather wants to enjoy hefty salaries for next 3-4 year on bleeding shareholder money.

3) They will keep on pumping Bavi just like they pumped Cotara. If you don't believe then call a neurosurgeon in China and they will tell you that TNT Cotata is junk.

Bavi value:

Bavi may have some value in future but as of today it MOA is doubtful and not convincing . BP may not be interested in Bavi due to below reasons.

- They wants to see results of their own single agent therapy PD1/PD-L1 before investing in Bavi , which is not shown single agent activity as of today.

- P2 Bavi result are questionable and p-value is not very encouraging .

- There are other drug which has more potential in immunotherapy space . These drugs seems to increase T-cell activity . One example is INO other may be LBIO.

- Bavi survival advantage is not co-related to PFS advantage , which raises lot of questions on its working mechanism.

- Chimeric antibody has a long history of failure.

ws